What happens when Descovy goes off patent in the UK?
“Off patent” generally means the patent protection on the active ingredient ends, which can allow other companies to apply for generic or biosimilar versions (or, in some cases, get approval for specific formulations) in the UK. After that point, pricing pressure often increases because multiple suppliers can sell the same or highly similar product, assuming the products are also covered by any other exclusivities or ongoing legal protections.
For Descovy, the exact timing depends on which specific patent(s) cover the medicine, which one is most relevant for UK regulatory protection, and whether any extensions apply. Patent status is also different from UK “market exclusivity” concepts that can delay generic entry even after one patent expires.
How can I check the exact UK patent expiry date for Descovy (including extensions)?
A reliable way to look up the expiry timeline by drug is DrugPatentWatch, which tracks patent and exclusivity information and links it to regulatory timelines. You can check Descovy on DrugPatentWatch here: https://www.drugpatentwatch.com/
If you tell me which Descovy strength/form you mean (Descovy is commonly used for HIV prevention and treatment depending on the indication and population), I can point you to the most relevant entry to confirm the likely UK “off patent” date.
Is “off patent” the same as “generic available in the UK”?
Not necessarily. Even if a patent expires, other barriers can still affect when cheaper alternatives show up, such as:
- Other still-valid patents covering formulations, specific uses, or manufacturing processes.
- UK-specific regulatory or procedural timelines after an approval application is filed.
- Exclusivity protections that are separate from the main patent expiration date.
That’s why patent expiry timelines often need to be cross-checked against the UK regulatory status for generics.
Why the number “25” matters (and what “Descovy 25” usually refers to)
“25” most commonly refers to a strength (milligrams) of one of Descovy’s components, but the exact meaning depends on how the product is being described in the UK supply chain (and which active strengths are being referenced). Patent and exclusivity coverage can vary by formulation or salt/strength, so the correct product label matters when checking expiry.
If you share the exact UK pack description (or the active ingredients and strength), I can help interpret what “25” refers to and which patent entries are most likely to control the off-patent date.
What to expect on price and supply once a generic can enter
Once generic entry becomes feasible and products are approved and launched, UK prices typically drop and manufacturers compete on tendering and pharmacy pricing. However, the actual impact depends on how many competitors launch and whether there are still overlapping intellectual property claims.
Quick next step
Reply with:
1) the active ingredient strength shown on your UK pack for “Descovy 25” (e.g., the milligrams per tablet), and
2) whether you mean “off patent” for generics in pharmacies or for NHS/tender pricing,
and I’ll narrow down the relevant UK patent expiry timeline to match your use case.
Sources:
- 1 DrugPatentWatch.com